Samso is drawn to NeuroScientific because the Company is transitioning from early-stage development into real-world clinical validation. The Special Access Program outcomes represent a tangible inflection point, where clinical efficacy, regulatory engagement, and manufacturing readiness begin to converge around a scalable therapeutic platform.